QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, March 31, 2004, 24(13):3436-3443; doi:10.1523/JNEUROSCI.0387-04.2004

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Baucum, A. J. Articles by Fleckenstein, A. E. Search for Related Content PubMed PubMed Citation Articles by Baucum, A. J., II Articles by Fleckenstein, A. E.

 Previous Article  |  Next Article 

Behavioral/Systems/Cognitive
Methamphetamine Increases Dopamine Transporter Higher Molecular Weight Complex Formation via a Dopamine- and Hyperthermia-Associated Mechanism

Anthony J. Baucum, II, Kristi S. Rau, Evan L. Riddle, Glen R. Hanson, and Annette E. Fleckenstein

Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112

Multiple high-dose administrations of methamphetamine (METH) both rapidly (within hours) decrease plasmalemmal dopamine (DA) uptake and cause long-term deficits in DA transporter (DAT) levels and other dopaminergic parameters persisting weeks to months in rat striatum. In contrast, either a single administration of METH or multiple administrations of methylenedioxymethamphetamine (MDMA) cause less of an acute reduction in DA uptake and little or no persistent dopaminergic deficits. The long-term dopaminergic deficits caused by METH have been suggested, in part, to involve the DAT. Hence, this study assessed the impact of METH and MDMA administration on the DAT protein per se. Results revealed that multiple administrations of METH promoted formation of higher molecular weight (>170 kDa) DAT-associated protein complexes 24–48 hr after treatment. This increase was attenuated by either preventing hyperthermia or pretreatment with the tyrosine hydroxylase inhibitor -methyl-p-tyrosine; notably, each of these manipulations has also been demonstrated previously to prevent the persistent deficits in dopaminergic function caused by METH treatment. In contrast, either a single injection of METH or multiple injections of MDMA caused little or no formation of these DAT complexes. The addition of the reducing agent -mercaptoethanol to samples prepared from METH-treated rats diminished the intensity of these complexes. Taken together, these data are the first to demonstrate higher molecular weight DAT complex formation in vivo and that such formation can be altered by both pharmacological and physiological manipulations. The implications of this phenomenon with regard to the neurotoxic potential of these stimulants are discussed.

Key words: psychostimulants; methamphetamine; methylenedioxymethamphetamine; oligomer; dopamine transporter; neurotoxicity

---

Received Nov 19, 2003; revised February 23, 2004; accepted February 28, 2004.

This article has been cited by other articles:

				G. C. Hadlock, A. J. Baucum II, J. L. King, K. A. Horner, G. A. Cook, J. W. Gibb, D. G. Wilkins, G. R. Hanson, and A. E. Fleckenstein Mechanisms Underlying Methamphetamine-Induced Dopamine Transporter Complex Formation J. Pharmacol. Exp. Ther., April 1, 2009; 329(1): 169 - 174. [Abstract] [Full Text] [PDF]

				J. L. Cornish, K. J. Clemens, M. R. Thompson, P. D. Callaghan, B. Dawson, and I. S. McGregor High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats J Psychopharmacol, January 1, 2008; 22(1): 100 - 110. [Abstract] [PDF]

				A. B. Alex, A. J. Baucum, and K. S. Wilcox Effect of Conantokin G on NMDA Receptor-Mediated Spontaneous EPSCs in Cultured Cortical Neurons J Neurophysiol, September 1, 2006; 96(3): 1084 - 1092. [Abstract] [Full Text] [PDF]

				D. M. Thomas and D. M. Kuhn Cyclooxygenase-2 Is an Obligatory Factor in Methamphetamine-Induced Neurotoxicity J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 870 - 876. [Abstract] [Full Text] [PDF]

				D. M. Thomas, P. D. Walker, J. A. Benjamins, T. J. Geddes, and D. M. Kuhn Methamphetamine Neurotoxicity in Dopamine Nerve Endings of the Striatum Is Associated with Microglial Activation J. Pharmacol. Exp. Ther., October 1, 2004; 311(1): 1 - 7. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help